X

Biotech

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big…

Biogen posts Q3 earnings well above estimates

Biogen (NASDAQ: BIIB) reported third-quarter 2021 financial results before the regular market hours on Wednesday. The company reported Q3 revenue…

Gilead Sciences, Inc (GILD): Q3 2019 Earnings Snapshot

-- Gilead Sciences (NYSE: GILD) reported third-quarter 2019 earnings of $1.75 per share, vs. $1.74 per share expected. -- Total…

Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew…

Thermo Fisher Scientific (TMO): Q3 2019 Earnings Snapshot

-- Thermo Fisher Scientific (NYSE: TMO) reported third-quarter 2019 earnings of $2.94 per share, vs. $2.87 per share expected. --…

Biogen (BIIB) Q3 profit rises 7% on spinal muscular atrophy drug addition

Biogen Inc. (NASDAQ: BIIB) reported a 7% increase in earnings for the third quarter of 2019 as spinal muscular atrophy…

4 biotech stocks that are ideal takeover targets

Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. It could be after years…

Bio-Path’s loss expands in Q2

Biotech company Bio-Path Holdings (NASDAQ: BPTH) reported a loss of $2.5 million or $0.87 per share for the second quarter…

Earnings preview: Will losses continue for Celsion in Q2

Celsion Corporation (NASDAQ: CLSN) is set to release its earnings results for the second quarter on Thursday before the market…

Progenics posts wider-than-expected loss in Q2

Progenics Pharmaceuticals (NASDAQ: PGNX) reported a wider loss in the second quarter due to higher costs and expenses despite a…

What to look for when Progenics Pharma posts Q2 earnings

Progenics Pharmaceuticals (NASDAQ: PGNX) is set to release its earnings results for the second quarter of 2019 on Friday before…

Is Advaxis exhausting its financial resources with the stock hitting a record low?

Advaxis Inc. (NASDAQ: ADXS) stock plunged to a record low of $1.54 on Tuesday as the late-stage biotech company has…

Cara Therapeutics Q1 loss widens but beats estimates

Cara Therapeutics Inc. (NASDAQ: CARA) reported a wider loss in the first quarter of 2019 due to higher costs and expenses.…

ImmunoGen is cheap ahead of Q1 earnings, but is it worth?

ImmunoGen Inc (NASDAQ: IMGN) is one of the worst performing stocks out there, losing about 78% of its value over…

Biocept narrows loss in Q4

Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares…

Earnings preview: What’s on the cards for Biocept in Q4

Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular…

Earnings: Affimed cuts down losses in 2018

Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in…

Onconova Therapeutics cuts down losses in 2018

Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in…

Earnings Preview: Aeterna Zentaris reporting Q4 results on Mar 26

Aeterna Zentaris (AEZS) is scheduled to report its fourth-quarter financial results on March 26, Tuesday, after the regular trading hours.…

What is NASH and which biotech firms are vying for the first-mover status

NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver…

Earnings: Trevena slips on wider-than-expected Q4 loss

Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market…